


Claims

- Sub A 51
1. A pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein (a) an ester of fluticasone or a solvate thereof as medicament and (b) a solubilising agent for assisting the solubilisation of the medicament in the aqueous carrier liquid.
 2. A pharmaceutical formulation according to claim 1 wherein the ester of fluticasone is a compound of formula (I)



- wherein R represents ethyl or a 5 membered heterocyclic aromatic ring containing 1 to 3 heteroatoms selected from O, N and S, optionally substituted by one or more methyl or halogen atoms or a solvate thereof.
3. A pharmaceutical formulation according to claim 2 wherein R represents ethyl (i.e. the fluticasone ester is fluticasone propionate).
4. A pharmaceutical formulation according to claim 2 wherein R represents furan-2-yl.
5. A pharmaceutical formulation according to claim 1 wherein the solubilising agent is a surfactant.
6. A pharmaceutical formulation according to claim 5 wherein the surfactant is selected from the group consisting of a α -[4-(1,1,3,3-tetramethylbutyl)phenyl]- ω -hydroxypoly(oxy-1,2-ethanediyl) polymer (also known as a octylphenoxypolyethoxyethanol) and a 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane.
7. A pharmaceutical formulation according to claim 4 wherein the solubilising agent is a surfactant selected from the group consisting of a α -[4-(1,1,3,3-tetramethylbutyl)phenyl]- ω -hydroxypoly(oxy-1,2-ethanediyl) polymer (also

known as a octylphenoxypolyethoxyethanol) and a 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane.

8. A pharmaceutical formulation according to claim 6 wherein the surfactant is a 4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane.
- 5 9. A pharmaceutical formulation according to claim 1 which further has dissolved therein a hydroxy containing organic co-solvating agent or phosphatidyl choline.
- 10 10. A pharmaceutical formulation according to claim 7 which further has dissolved therein a hydroxy containing organic co-solvating agent or phosphatidyl choline.
11. A pharmaceutical formulation according to claim 9 wherein the the hydroxy containing organic co-solvating agent is dextrose.
12. A pharmaceutical formulation according to claim 10 wherein the the hydroxy containing organic co-solvating agent is dextrose.
- 15 13. A container containing a pharmaceutical formulation according to claim 1 fitted with a metering valve.
14. A device adapted for intranasal delivery of a pharmaceutical formulation comprising a container according to claim 13.
- 20 15. A method of treatment of inflammatory and/or allergic conditions of the nasal passages which comprises administering to the nose a pharmaceutical formulation according to claim 1.

add
A'